THERAPY DOSSIER · th-7403fb9c93fd

Tissue plasminogen activator (tPA) loaded polycaprolactone nanofibrous scaffold

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32852719 ↗2020Reported benefit

Tissue Plasminogen Activator Loaded PCL Nanofibrous Scaffold Promoted Nerve Regeneration After Sciatic Nerve Transection in Male Rats.

RatOthermalen = 24 mature male rats, divided into four groups (control, axo…implanted scaffold at the transection siteat the time of surgical repair

Model: Sciatic nerve transection (axotomy)

Stereological parameters, GFAP immunohistochemistry and S100, NGF and BDNF gene expression were significantly higher in the tPA-loaded scaffold group than in the axotomy group, with results closest to those of the control group, indicating good functional nerve tissue regeneration over a short peri…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…